Showing results (81-90 of 100) with videos related to
Sort By:
Pageof 10
The New England Journal of Medicine|October 22, 2025
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLCWenfeng Fang, Lin Wu, Xiangjiao Meng, et al.Nature Medicine|March 14, 2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Yunpeng Yang, Yan Huang, et al.Translational Lung Cancer Research|November 19, 2020
Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter studyChun-Wei Xu, Wen-Xian Wang, Dong Wang, et al.Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.The Lancet. Respiratory Medicine|October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Jianya Zhou, Jianying Zhou, et al.The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.Pageof 10